Aptose Biosciences (APTO) Downgraded by ValuEngine to Strong Sell
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.
APTO has been the topic of several other research reports. Canaccord Genuity set a $7.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 15th. Zacks Investment Research upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Finally, HC Wainwright set a $4.00 target price on Aptose Biosciences and gave the stock a “buy” rating in a research report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $5.00.
Aptose Biosciences (NASDAQ:APTO) opened at $2.82 on Thursday. Aptose Biosciences has a 12 month low of $0.78 and a 12 month high of $3.90. The company has a market capitalization of $82.73, a P/E ratio of -4.41 and a beta of 2.81.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.